The HemoScreen hematology point‐of‐care device is suitable for rapid evaluation of acute leukemia patients

Abstract

Background Hematological patients, receiving intensive chemotherapy (predominantly acute leukemia patients), have repeated postchemotherapy periods with severe bone marrow suppression. As a result, these patients require regular monitoring of the complete blood counts (CBC) for optimal patient care. To reduce the strain on the patient, there is a need for a point‐of‐care (POC) hematology device that provides rapid and reliable results both in general and in cytopenic samples and is suitable for outpatient clinics. We evaluated the HemoScreen device for the most used CBC parameter both overall and at the lower range. Methods The HemoScreen was compared with the Sysmex XN‐9000 in 206 routine venous samples and 79 capillary bedside samples focusing on white blood cells (WBC), absolute neutrophil count (ANC), red blood cells (RBC), PLT and HGB. Results The HemoScreen was less precise compared to the acceptance criteria set for larger and more advanced hematology instrument with a CV% 3.0‐3.7 for WBCs, 3.6‐8.4 for ANCs, 1.1‐1.5 for RBCs, 2.5‐4.4 for PLTs, and 1.7‐2.3 for HGB. Correlation coefficient for all five parameters for the entire range was r >.95 and r >.90 at lower range for venous and capillary samples. Bias limits were within the CTCAE acceptance limits. Conclusions The HemoScreen provides rapid and accurate test results, for evaluation of WBC, PLT, and HGB, as well as at low concentrations for guiding transfusions and postchemotherapy treatment. The device is easy to operate and can measure both venous and capillary samples. Therefore, the HemoScreen is well suited for smaller outpatient clinics and potentially home use.

Clinical Prediction of Blood Parameters Associated with Breast, Colon, Thyroid, Ovarian, and Prostate Cancer

“…[13,14] Other studies showed that, using the CBC profiles to measure a patient's risk of health outcomes may indicate different infections or leukemia. [16] The rates of RBC were normal in all patients with cancer of various types except one breast cancer patient who had a very low rate of RBC, which indicate some vitamin deficiency or anemia. According to prior studies conducted in 2020, patients are rated based on quantitative changes in blood parameters related to the body's response to stress caused by malignant tumors.…”

HemoScreen hematology analyzer compared to Sysmex XN for complete blood count, white blood cell differential, and detection of leukocyte abnormalities

“…With intensive care patients, HemoScreen gave good correlation for platelet, WBC and red blood cell (RBC) concentrations compared to Sysmex XN, although the bias was positive at higher platelet and WBC concentrations [9]. Another study with acute leukemia patients showed similar trend for platelets and WBC with a good correlation for complete blood count (CBC), absolute neutrophil count and hemoglobin compared to Sysmex XN [10]. None of these studies investigated the performance on full WBC differential or the analyzer's ability to detect WBC abnormalities, even though there is technology and built‐in algorithms for this.…”

Low-intensity induction in acute myeloid leukemia. Always in the patients' best interest?

“…To reduce outpatient supportive care visits, home monitoring of laboratory parameters 6 and home transfusions are possible. Logistically these are difficult as they require significant resources including home nursing, early and systematic sample collection and close outpatient monitoring.…”